GlassScriptPhysician profile
Jeffrey A Morris
NPI 1497710685
$3,516.21
in general payments reported to CMS, 2019-2025
35 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $679 · 2021: $340 · 2022: $441 · 2023: $660 · 2024: $253 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.64 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $401.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $336.54 | 2020-2025 | Mounjaro, Zepbound, Humulin |
| Pfizer INC. | $282.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $261.96 | 2021-2023 | Xarelto |
| Abbvie INC. | $253.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.38 | 2020-2024 | Ofev, Glyxambi, Jardiance |
| Corcept Therapeutics | $177.88 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $118.77 | 2020-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $100.80 | 2020-2021 | |
| Glaxosmithkline, LLC. | $88.69 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $86.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.23 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.28 | 2022-2025 | |
| Abbott Laboratories | $65.42 | 2020-2024 | Freestyle Libre 3 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.